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Game Changers
TRANSANAL ENDOSCOPIC MICROSURGERY 
– CHANGING THE MANAGEMENT OF EARLY 
RECTAL CANCER
Mr Robert A. J. Spence, Ms Paula M. Loughlin, Mr Roger 
E. Lawther
Department of Surgery, Altnagelvin Hospital, Glenshane 
Road, BT47 6SB 
Rectal cancer is the fifth most common cancer in adults. 
While the management of rectal cancer has become 
increasingly multimodal, surgical excision in the form of 
anterior resection, or abdomino-perineal excision, remains 
the primary intervention.  There is debate about the optimum 
surgical approach to early stage rectal cancer (T1,N0), and 
endoscopically unresectable rectal polyps.
Transanal endoscopic microsurgery (TEM) has emerged 
as a less invasive alternative to traditional surgery.  It is 
the intraluminal excision of a rectal lesion, with a clear, 
magnified view, using an operating rectoscope, allowing for 
organ-preserving surgery.  TEM has a number of advantages 
over radical surgery, including avoidance of stoma, decreased 
pain, faster recovery, and much shorter hospital stay, 
typically 24 hours.  Importantly, several studies comparing 
TEM to radical abdominal surgery show no significant 
difference in recurrence (4-8%), or survival.  A recent meta-
analysis comparing TEM with standard trans-anal surgery 
demonstrated a lower rate of margin involvement, decreased 
tumour recurrence, and reduced specimen fragmentation 
with TEM.
Careful patient selection is essential.  TEM is now an accepted 
treatment for large benign polyps and early low risk rectal 
cancers (T1), which have no adverse pathological features. 
High-risk T1 tumours with poor differentiation and lymphatic 
involvement are better served with conventional resection. 
The use of TEM in node negative T2 and T3 tumours is 
unclear and requires further study.  There is a role for TEM 
in the palliation of those with advanced rectal cancers, that 
due to co-morbidity, or metastatic disease, are unfit for 
major resection.  As the use of this technique becomes more 
widespread, there are implications for service planning and 
training. 
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ENDOVASCULAR THERAPY FOR ACUTE 
ISCHAEMIC STROKE
Dr Paul A Burns. 
Department of Radiology, Royal Victoria Hospital, Belfast, 
BT12 6BA
Stroke secondary to proximal vascular occlusion has a poor 
natural history unless rapid recanalization can be achieved. 
Unfortunately intravenous thrombolysis has modest efficacy 
at achieving this in the setting of a large clot burden1. 
Endovascular therapy (mechanical thrombectomy) via 
utilizing a retrievable stent has shown promise to effect the 
rapid recanalization required.
The Royal Victoria Hospital, Belfast Trust was recently 
the sole UK recruiting centre for the ESCAPE trial1, which 
compared outcome in anterior circulation stroke patients 
treated with endovascular therapy plus standard care 
versus standard care alone.  Patients were selected into 
the study based on advanced CT imaging criteria, which 
had to demonstrate a small core infarct, proximal vascular 
occlusion and salvageable brain (that is ischemic, but not 
yet irreversibly infarcted).  For patients randomized into the 
endovascular arm, emphasis was put on procedural speed, 
with a target CT to groin puncture of <60 minutes and groin 
puncture to procedure completion of <30 minutes.  
The study demonstrated that the rate of functional 
independence at 90 days from stroke onset increased from 
29.3% to 53.0% in the endovascular group and there was a 
decrease in mortality from 19.0% to 10.4%.
The American Heart Association/American Stroke 
Association in their updated guidelines has now endorsed 
endovascular therapy for selected stroke patients2.  As this 
therapy becomes standard of care, the challenge for us in 
Northern Ireland is to fully implement a 24/7 service and to 
ensure that patients eligible for this treatment are transferred 
as quickly as possible to benefit from it.  
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A NEW DAWN FOR THE TREATMENT OF CYSTIC 
FIBROSIS
Dr Peter Doherty & Dr DG Downey
Belfast City Hospital, Belfast Health and Social Care Trust, 
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Cystic Fibrosis (CF) is an inherited, life limiting, multisystem 
disease characterized by viscid secretions in multiple organ 
systems. Progressive respiratory failure remains the most 
common cause of morbidity and mortality with a current 
median survival of 41 years. The disease affects over 10,000 
people in the United Kingdom. The mainstay of therapy is 
the treatment and reduction of respiratory infections and 
optimizing nutritional status.
Cystic fibrosis is caused by a defect in the Cystic Fibrosis 
Transmembrane Conductance Regulator (CFTR) gene causing 
altered chloride and water transport. Over 2,000 different 
mutations of this gene have been described although not all 
cause CF. Approximately 50% of patients are homozygous 
for the ΔF508 mutation.
Ivacaftor (Kalydeco) is the first in a new class of 
transformative medications known as CFTR Modulators. It 
improves the transport of chloride across the cell membrane 
resulting in a significant increase in lung function and a 
reduction in respiratory infections.1 It is licensed for use in 
patients with the G551D and other similar mutations (5-10% 
of patients). 
More recently two positive phase III trials have been 
completed to assess the efficacy of Ivacaftor along 
with another CFTR Modulator, Lumacaftor, in patients 
homozygous for the ΔF508 mutation.2 This combination 
therapy (Orkambi) is currently licensed in the US with a 
European Medicine Agency review expected later in 2015. 
However, these drugs are expensive and the cost per quality 
adjusted life year (QALY) for Ivacaftor is between £285,000 
and £1,077,000.3 There are several new CFTR modulators 
undergoing clinical trials at present.
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